Kum K. Khanna

300 Herston Road
Herston, QLD 4006, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 175 publications

Editorial Note: Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.

Editorial Note: Heregulin-HER3-HER2 signaling promotes matrix metalloproteinase-dependent blood-brain-barrier transendothelial migration of human breast cancer cell lines.

Journal: Oncotarget
Published: July 24, 2026

Genetic Ablation and Multi-Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models.

Genetic Ablation and Multi-Omics Profiling Reveal CEP55 as a Key Driver of Tumorigenesis in Diverse Cancer Models.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: November 27, 2025

Redox regulation of EGFR activation by thioredoxin reductase 3 drives resistance to EGFR inhibitors in triple-negative breast cancer.

Redox regulation of EGFR activation by thioredoxin reductase 3 drives resistance to EGFR inhibitors in triple-negative breast cancer.

Journal: Cell death discovery
Published: November 06, 2025

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Author Correction: Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus.

Journal: Nature communications
Published: September 09, 2025

Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Correction: CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Journal: Oncogene
Published: March 03, 2025

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

CBL0137 and NKG2A blockade: a novel immuno-oncology combination therapy for Myc-overexpressing triple-negative breast cancers.

Journal: Oncogene
Published: February 14, 2024

Targeting chromosomal instability and aneuploidy in cancer.

Targeting chromosomal instability and aneuploidy in cancer.

Journal: Trends in pharmacological sciences
Published: December 21, 2023

Defining the relationship between cellular and extracellular vesicle (EV) content in breast cancer via an integrative multi-omic analysis.

Defining the relationship between cellular and extracellular vesicle (EV) content in breast cancer via an integrative multi-omic analysis.

Journal: Proteomics
Published: May 18, 2023

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis.

COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis.

Journal: Journal of experimental & clinical cancer research : CR
Published: December 10, 2022

Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice.

Alpha-B-Crystallin overexpression is sufficient to promote tumorigenesis and metastasis in mice.

Journal: Experimental hematology & oncology
Published: October 06, 2022

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.

CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.

Journal: Journal of experimental & clinical cancer research : CR
Published: September 19, 2022

Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma.

Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: July 06, 2022
Showing 1-12 of 175

Last Updated: 09/26/2026